Conversely, a 2023 case report from our group described a patient with IBD who developed worsening back pain following treatment with vedolizumab, an anti-α4β7 monoclonal antibody, which improved when switched to an anti-TNF monoclonal antibody [19]. The gene discussed is TNF; the disease is inflammatory bowel disease.